Clinical experience with the Intertach 262-12 pulse generator in patients with recurrent supraventricular and ventricular tachycardia.
An antitachycardia pulse generator, the Intermedics Intertach 262-12 was implanted in 16 patients (14 patients with supraventricular tachycardia of various origins and two patients with recurrent ventricular tachycardia), who were not responsive to various antiarrhythmic drug regimens. The follow-up was from 6-49 months (mean 30.9 +/- 13.8). Five patients had a follow-up of over 3 years. The device was used in all patients. One patient with ventricular tachycardia died from a nonarrhythmic cause. Loss of responsiveness to burst pacing was observed in 1/14 patients with supraventricular tachycardia and nontolerance of antitachycardia pacing in one patient. Overall clinical success of pacing was observed in 13/16 patients = 81%. The pacemaker proved to be a versatile system with reliable tachycardia detection and termination functions.
Fromer
M
M
Division of Cardiology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
Gloor
H
H
Kus
T
T
Kappenberger
L
L
Shenasa
M
M
D000328:Adult; D000368:Aged; D001281:Atrial Fibrillation / Q000503:physiopathology / Q000517:prevention & control; D002304:Cardiac Pacing, Artificial / Q000379:methods*; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004867:Equipment Design; D004868:Equipment Failure; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010138:Pacemaker, Artificial; D012008:Recurrence; D013610:Tachycardia / Q000503:physiopathology / Q000628:therapy*; D013617:Tachycardia, Supraventricular / Q000503:physiopathology / Q000628:therapy*
D004071:Digitalis Glycosides